11 November 2021 - UK vs EPO tests for obviousness – one inventive step at a time

11 November 2021 - UK vs EPO tests for obviousness – one inventive step at a time

Kilburn & Strode’s Life Sciences & Chemistry team invites you to our latest breakfast event contrasting the approach of the European Patent Office to the patentability of chemical inventions with that of the UK courts.

 

UK vs EPO tests for obviousness – one inventive step at a time

 

About the event
If my case is inventive at the EPO, it’ll be fine at the UK Courts, right?

Right?

While both UK and EPO require that your claimed invention comprises an inventive step, the way they assess this ground is very different in practice. Join Kathryn Eldridge and Katherine Moggridge in a fireside chat where they will unravel the complexities of inventive step and demystify the approach taken by these two renowned judiciaries. They will cover the key aspects of the UK and European approaches, illustrated with their own experiences from the frontline before the Boards of Appeal and the UK Courts.

Join us on 11 November 2021 for a hybrid event at our London offices or via Zoom. Our speakers will host a fireside chat with live Q&A and discuss the following:

  • The differences in the underlying tests for inventive step.

  • How we approach defending and attacking Patents on this ground.

  • Common pitfalls of the two approaches, and how to deal with them.

We hope you will be able to join us for this event. 

To ensure that we maintain some social distance, we are limiting the numbers for our in-person event, so sign up now to secure your place in our offices. Virtual places are unlimited!

When:
Thursday 11 November 2021

Time: 
09:00 - 09:45 GMT
 

 

Let us keep you up to date. If you’d like to receive communications from us, ranging from breaking news to technical updates, thought leadership to event invitations, please let us know.

Connect with us

Cookies improve the way our website works. By using this website you are agreeing to our use of cookies. For more information see our cookie policy I accept